XFOR

X4 Pharmaceuticals Inc

XFOR, USA

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company also develops mavorixafor that is in Phase 3 4WARD clinical trial to evaluate the efficacy, safety, and tolerability of oral, once-daily mavorixafor with or without stable doses of G-CSF in people with congenital, acquired primary autoimmune, or idiopathic CN who are experiencing recurrent and/or serious infections. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications; and with Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand. The company is headquartered in Boston, Massachusetts.

https://www.x4pharma.com

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
XFOR
stock
XFOR

What hedge funds are buying XFOR - Stock Surge & Fast Entry Momentum Trade Alerts bollywoodhelpline.com

Read more →
XFOR
stock
XFOR

Sentiment Review: Whats the beta of XFOR stock - Market Activity Report & AI Enhanced Trade Execution Alerts baoquankhu1.vn

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$8

Analyst Picks

Strong Buy

3

Buy

2

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.48

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-48.39 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-18.23 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-1,746.29 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

1.65

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 10.61% of the total shares of X4 Pharmaceuticals Inc

2.

Kingdon Capital Management LLC

(1.0394%)

since

2025/06/30

3.

Vanguard Group Inc

(1.033%)

since

2025/06/30

4.

BlackRock Inc

(0.7984%)

since

2025/06/30

5.

Vanguard Total Stock Mkt Idx Inv

(0.6936%)

since

2025/07/31

6.

GSA Capital Partners LLP

(0.5912%)

since

2025/06/30

7.

UBS Group AG

(0.4898%)

since

2025/06/30

8.

Jane Street Group LLC

(0.4336%)

since

2025/06/30

9.

Bank of America Corp

(0.3578%)

since

2025/06/30

10.

UBS O'Connor LLC

(0.3564%)

since

2025/06/30

11.

Millennium Management LLC

(0.3477%)

since

2025/06/30

12.

Pale Fire Capital SE

(0.2675%)

since

2025/06/30

13.

Geode Capital Management, LLC

(0.2189%)

since

2025/06/30

14.

Vanguard Institutional Extnd Mkt Idx Tr

(0.1975%)

since

2025/07/31

15.

Squarepoint Ops LLC

(0.1736%)

since

2025/06/30

16.

Susquehanna International Group, LLP

(0.1551%)

since

2025/06/30

17.

AQR Capital Management LLC

(0.1175%)

since

2025/06/30

18.

Fidelity Extended Market Index

(0.1082%)

since

2025/07/31

19.

Point72 Asset Management, L.P.

(0.0965%)

since

2025/06/30

20.

Goldman Sachs Group Inc

(0.084%)

since

2025/06/30

21.

AQR Small Cap Multi-Style I

(0.0832%)

since

2025/06/30

22.

Renaissance Technologies Corp

(0.0774%)

since

2025/06/30

23.

State Street Corp

(0.0692%)

since

2025/06/30

24.

Extended Equity Market Fund K

(0.0494%)

since

2025/06/30

25.

Fidelity Total Market Index

(0.0352%)

since

2025/07/31

26.

Fidelity Series Total Market Index

(0.0297%)

since

2025/07/31

27.

Rhumbline Advisers

(0.028%)

since

2025/03/31

28.

Spartan Extended Market Index Pool F

(0.0216%)

since

2025/07/31

29.

Northern Trust Extended Eq Market Idx

(0.0214%)

since

2025/06/30

30.

NT Ext Equity Mkt Idx Fd - L

(0.0214%)

since

2025/06/30

31.

NT Ext Equity Mkt Idx Fd - NL

(0.0176%)

since

2025/06/30

32.

Vanguard Instl Ttl Stck Mkt Idx Tr

(0.0168%)

since

2024/12/31

33.

Fidelity Nasdaq Composite Index

(0.014%)

since

2025/07/31

34.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0136%)

since

2025/06/30

35.

Spartan Total Market Index Pool G

(0.0134%)

since

2025/07/31

36.

Vifag 2002 SICAV

(0.0111%)

since

2025/07/31

37.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0051%)

since

2024/12/31

38.

SSgA Russell Small Cap Completeness Idx

(0.0035%)

since

2025/03/31

39.

SSgA Russell 2000 Growth Index Strategy

(0.0025%)

since

2025/03/31

40.

SSgA U.S. Total Market Index Strategy

(0.0021%)

since

2025/03/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.69

EPS Estimate

-0.125

EPS Difference

-0.565

Surprise Percent

-452%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(1.5)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(3.5)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(1.5)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.